Condition

Schizophrenia Relapse

ClinicalTrials.gov condition label

Clinical trials6

Recruiting0

Common interventions6

Lead sponsors shown5

Clinical trials

6 shown

Risk of Breakthrough Symptoms With Long-Acting Injectable MedicationsNCT05473741 · 2023-01-11

Indoor Artificial Light at Night and the Relapse Risk of SchizophreniaNCT05986409 · 2022-08-01

Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis RelapseNCT03558529 · 2015-05-01

10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis IndividualsNCT03090490 · 2014-09-01

Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose ReductionNCT03019887 · 2011-04-01

3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis IndividualsNCT02220504 · 2004-07-01

Common interventions

Antipsychotic treatment discontinuationOTHER2 light coverOTHER1 Maintenance antipsychotic treatmentOTHER1 Maintenance treatment discontinuationOTHER1 reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazineDRUG1 Second Generation Long-Acting Injectable Antipsychotic MedicationsDRUG1

Leading sponsors

Fundación Marques de Valdecilla2 Centre for Addiction and Mental Health1 Juntendo University1 Manchester Academic Health Science Centre1 Weizhuo Yi1

Trial status mix

COMPLETED5

UNKNOWN1

Phase mix

NA4

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.